Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Harmony Biosciences: Unnoticed Melodies Of Portfolio Growth And Pipeline Potential
Harmony Biosciences' main product, WAKIX, drives significant revenue growth, with expansion potential in treating narcolepsy and other conditions, despite past controversies. The company's strategic acquisitions, including Zynerba and Epygenix, aim to diversify its portfolio, reducing reliance on WAKIX and boosting long-term growth prospects. Harmony's financial health is strong, with substantial cash reserves and high margins, allowing continued investment in research and development.
Surging Earnings Estimates Signal Upside for Harmony Biosciences (HRMY) Stock
Harmony Biosciences (HRMY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Harmony Biosciences: Advancing An Expanded Pipeline
Today, we are revisiting the biopharma name Harmony Biosciences for the first time in nearly a year and a half. The company is nicely profitable thanks to its flagship product WAKIX and Harmony has a solid balance sheet as well. Harmony Biosciences has made some recent acquisitions that greatly expanded its pipeline and peak sales potential.
Can Harmony Biosciences (HRMY) Climb 25.05% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
HRMY vs. REGN: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?
Should Value Investors Buy Harmony Biosciences (HRMY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q2 Earnings and Revenue Estimates
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.56 per share a year ago.
HRMY or REGN: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?
Wall Street Analysts See a 32.82% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 32.8% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
Amalgamated Bank Lowers Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Amalgamated Bank lessened its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) by 8.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 14,003 shares of the company’s stock after selling 1,239 shares during the quarter. Amalgamated Bank’s holdings in Harmony Biosciences were worth $452,000 as of its most recent filing with the Securities & Exchange Commission. A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Summit Global Investments purchased a new position in shares of Harmony Biosciences in the 4th quarter valued at approximately $522,000. Los Angeles Capital Management LLC increased its position in Harmony Biosciences by 218.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 24,148 shares of the company’s stock valued at $780,000 after buying an additional 16,555 shares in the last quarter. Jackson Creek Investment Advisors LLC bought a new position in Harmony Biosciences during the 4th quarter valued at approximately $991,000. Paradiem LLC increased its position in Harmony Biosciences by 38.7% during the 4th quarter. Paradiem LLC now owns 107,031 shares of the company’s stock valued at $3,457,000 after buying an additional 29,847 shares in the last quarter. Finally, Truist Financial Corp bought a new position in Harmony Biosciences during the 4th quarter valued at approximately $297,000. Hedge funds and other institutional investors own 86.23% of the company’s stock. Wall Street Analysts Forecast Growth A number of research analysts recently weighed in on HRMY shares. Mizuho reduced their price objective on Harmony Biosciences from $42.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $49.00 price objective on shares of Harmony Biosciences in a research report on Friday, April 12th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $50.00 target price on shares of Harmony Biosciences in a report on Tuesday, April 30th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Harmony Biosciences currently has an average rating of “Moderate Buy” and an average target price of $40.63. Read Our Latest Report on HRMY Harmony Biosciences Stock Down 1.0 % Harmony Biosciences stock opened at $29.03 on Monday. The company has a current ratio of 3.11, a quick ratio of 3.07 and a debt-to-equity ratio of 0.34. Harmony Biosciences Holdings, Inc. has a 12 month low of $18.61 and a 12 month high of $39.26. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of 12.57, a PEG ratio of 0.47 and a beta of 0.75. The stock has a fifty day simple moving average of $30.88 and a two-hundred day simple moving average of $30.86. Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.60 by $0.07. Harmony Biosciences had a return on equity of 28.26% and a net margin of 22.30%. The company had revenue of $154.62 million during the quarter, compared to analyst estimates of $154.10 million. During the same quarter in the previous year, the company posted $0.48 earnings per share. Harmony Biosciences’s revenue was up 29.8% compared to the same quarter last year. Equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.53 EPS for the current fiscal year. Insider Buying and Selling In related news, insider Jeffrey Dierks sold 11,979 shares of Harmony Biosciences stock in a transaction on Friday, March 15th. The stock was sold at an average price of $32.00, for a total value of $383,328.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 30.80% of the stock is currently owned by corporate insiders. About Harmony Biosciences (Free Report) Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Read More Five stocks we like better than Harmony Biosciences The How And Why of Investing in Oil Stocks MarketBeat Week in Review – 5/13 – 5/17 Canadian Penny Stocks: Can They Make You Rich? Take-Two Interactive Software Offers 2nd Chance for Investors Transportation Stocks Investing Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report).
